When communicating an unexpected safety signal to senior management, what should a regulatory affairs professional prioritize in the initial communication?
-
A
Detailed statistical analysis of all clinical trial data
-
B
Clear summary of the risk, regulatory implications, and recommended actions
-
C
A complete literature review of similar signals in competing products
-
D
Final labeling language changes ready for immediate submission